RT Journal Article
SR Electronic
T1 A Meta-analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation and Adverse Effects with Ivermectin Use in COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.30.21256415
DO 10.1101/2021.04.30.21256415
A1 Karale, Smruti
A1 Bansal, Vikas
A1 Makadia, Janaki
A1 Tayyeb, Muhammad
A1 Khan, Hira
A1 Ghanta, Shree Spandana
A1 Singh, Romil
A1 Tekin, Aysun
A1 Bhurwal, Abhishek
A1 Mutneja, Hemant
A1 Mehra, Ishita
A1 Kashyap, Rahul
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.04.30.21256415.abstract
AB Importance/Background Despite the global healthcare’s exhaustive efforts to treat COVID-19, we still do not have an effective cure for it. Repurposing Ivermectin, a known antiparasitic agent, for treating COVID-19 has demonstrated positive results in several studies. We aim to evaluate the benefit and risk of Ivermectin in COVID-19.Methods We conducted a systematic search for full-text manuscripts published from February 1, 2020 to March 27, 2021 that focused on efficacy and safety of Ivermectin therapy against COVID-19. The primary outcomes were overall mortality, need for intensive care unit (ICU) admission; secondary outcomes were - adverse effects, need for mechanical ventilation. Random-effects models were used for all analysis.Results We included a total of 38 studies (n=15,002) in the qualitative analysis (Mortality N=28, ICU admission= 8, Mechanical Ventilation= 10, Adverse events=28) and out of these, 30 studies (n=11,291) were included in the quantitative analysis (Mortality N=22, ICU admission= 5, Mechanical Ventilation= 9, Adverse events=17). In the mortality meta-analysis, odds of death were lower in the Ivermectin-arm compared to the non-Ivermectin arm. (OR 0.39, 95% CI 0.22-0.70; I2=81%). Subgroup analysis of 12 randomized controlled trials with severity-based data showed mortality benefit overall (OR 0.33, 95% CI 0.15-0.72; I2=53%) and in the mild/moderate sub-group (OR 0.10, 95% CI 0.03-0.33; I2=0%). Benefit of Ivermectin in decreasing; the need for ICU admission (OR 0.48, 95% CI 0.17-1.37; I2=59%) and mechanical ventilation (OR 0.64, 95% CI 0.40-1.04; I2=17%) was not significant. The quantitative analysis of adverse effects with Ivermectin use was inconclusive (OR 0.92, 95% CI 0.64-1.33; I2=14%).Conclusion Our meta-analysis suggests that Ivermectin could be an effective adjuvant therapy in reducing mortality, particularly in patients with mild-moderate clinical presentation of COVID-19. Trends of decreased need for ICU admissions and mechanical ventilation were observed but were not significant. The analysis for adverse effects was inconclusive.What We Already Know about This TopicCOVID-19 is an ongoing global pandemic, for which Ivermectin has been tried on a therapeutic and prophylactic basis.Results from several clinical trials and observational studies suggest that Ivermectin may improve survival and clinical outcomes with a good safety profile when compared with other treatments; however, the current evidence is limited.What This Article Tells Us That Is NewThis systematic review and meta-analysis provide a summary of the latest literature on the efficacy and safety of Ivermectin use for COVID-19.Based on our quantitative and qualitative analysis, we found that Ivermectin may be a potentially useful adjuvant therapy in reducing mortality, the need for ICU admissions and mechanical ventilation in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no financial disclosure related to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was required for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available on our site.CDCCenters for Disease Control and PreventionCOVID-19Coronavirus Disease 2019DNADeoxyribonucleic AcidFDAFood and Drug AdministrationFLCCCFront line COVID-19 Critical CareICUIntensive Care UnitIRBInstitutional Review BoardNIHNational Institutes of HealthRCTRandomized controlled trialRNARibonucleic AcidRT-PCRReverse Transcription Polymerase Chain ReactionIMPImportinSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2WHOWorld Health Organization